Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer.
Daniel ReinhornRinat YerushalmiAssaf MooreAlexandra DesnoyersRamy R SalehEitan AmirHadar GoldvaserPublished in: Breast cancer research and treatment (2020)
The increased risk of bone fractures associated with adjuvant AIs falls over time and after discontinuation of treatment. Differences in other toxicities between AIs and tamoxifen do not change significantly over time including a persistently elevated risk of cardiovascular events.
Keyphrases
- early stage
- postmenopausal women
- cardiovascular events
- bone mineral density
- coronary artery disease
- cardiovascular disease
- sentinel lymph node
- body composition
- breast cancer cells
- type diabetes
- squamous cell carcinoma
- estrogen receptor
- combination therapy
- positive breast cancer
- soft tissue
- radiation therapy
- mesenchymal stem cells
- young adults
- smoking cessation
- locally advanced